Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 5/20 | 0.49 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29088608 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL19135675 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL28815580 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL12961023 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL8041217 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL6924150 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL28589078 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL18597022 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL18597123 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 | |
| SCHEMBL28589077 | 1.00 | LMNA (0.55) | LMNACA2FAAHZDHHC7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| WO-2008034032-A2 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, FAAH2 | LMNA 3881/4885CA2 1387/4885FAAH 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.